Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2016

01-01-2016 | Epidemiology

Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence

Authors: Joel M. Brothers, Kelley M. Kidwell, Richard K. J. Brown, N. Lynn Henry

Published in: Breast Cancer Research and Treatment | Issue 2/2016

Login to get access

Abstract

Despite guidelines recommending against its routine use, perioperative imaging for distant metastases is frequently performed in newly diagnosed breast cancer patients, uncovering incidental findings of uncertain significance. We assessed the clinical significance of incidental findings by determining if their presence is associated with disease recurrence. A retrospective review of staging imaging was performed in patients with stage II or III invasive breast cancer diagnosed during 2008–2009 at a large academic medical center. Data related to perioperative imaging and disease recurrence were abstracted from the medical record. Kaplan–Meier curves and Cox proportional hazards models were used to assess the association between incidental findings and time to disease recurrence. A total of 169 of 340 patients (49.7 %) underwent staging evaluation for distant metastases (CT chest, abdomen, pelvis, bone scan, and/or PET-CT). Of these, 146 (86.4 %) had at least one suspicious or indeterminate finding. Follow-up studies were performed in 73 (43.2 %) patients. Nineteen patients were diagnosed with metastatic disease at diagnosis, 18 of whom had stage III disease. In patients without metastatic disease at diagnosis, 32 later developed recurrence. Non-calcified pulmonary nodules were associated with shorter time to disease recurrence (hazard ratio 2.51, 95 % CI 1.13–5.57, p = 0.02). Imaging for distant metastases frequently reveals indeterminate findings, most of which are not associated with disease recurrence. The association between pulmonary nodules and recurrence warrants validation in an independent cohort. Overall, these findings support current guidelines recommending against routine extent of disease evaluation in patients with newly diagnosed stage II breast cancer.
Appendix
Available only for authorised users
Literature
1.
go back to reference Puglisi F, Follador A, Minisini AM et al (2005) Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 16(2):263–266CrossRefPubMed Puglisi F, Follador A, Minisini AM et al (2005) Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 16(2):263–266CrossRefPubMed
2.
go back to reference Kasem AR, Desai A, Daniell S, Sinha P (2006) Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer. Breast J 12(6):544–548CrossRefPubMed Kasem AR, Desai A, Daniell S, Sinha P (2006) Bone scan and liver ultrasound scan in the preoperative staging for primary breast cancer. Breast J 12(6):544–548CrossRefPubMed
3.
go back to reference Kim H, Han W, Moon HG et al (2011) The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma. Breast Cancer Res Treat 126(3):637–641CrossRefPubMed Kim H, Han W, Moon HG et al (2011) The value of preoperative staging chest computed tomography to detect asymptomatic lung and liver metastasis in patients with primary breast carcinoma. Breast Cancer Res Treat 126(3):637–641CrossRefPubMed
4.
go back to reference Gerber B, Seitz E, Muller H et al (2003) Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Res Treat 82(1):29–37CrossRefPubMed Gerber B, Seitz E, Muller H et al (2003) Perioperative screening for metastatic disease is not indicated in patients with primary breast cancer and no clinical signs of tumor spread. Breast Cancer Res Treat 82(1):29–37CrossRefPubMed
5.
go back to reference Schnipper LE, Smith TJ, Raghavan D et al (2012) American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 30(14):1715–1724CrossRefPubMed Schnipper LE, Smith TJ, Raghavan D et al (2012) American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol 30(14):1715–1724CrossRefPubMed
7.
go back to reference Simos D, Hutton B, Clemons M (2015) Are physicians choosing wisely when imaging for distant metastases in women with operable breast cancer? J Oncol Pract 11(1):62–68CrossRef Simos D, Hutton B, Clemons M (2015) Are physicians choosing wisely when imaging for distant metastases in women with operable breast cancer? J Oncol Pract 11(1):62–68CrossRef
8.
go back to reference Crivello ML, Ruth K, Sigurdson ER et al (2013) Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population. Ann Surg Oncol 20(1):102–110PubMedCentralCrossRefPubMed Crivello ML, Ruth K, Sigurdson ER et al (2013) Advanced imaging modalities in early stage breast cancer: preoperative use in the United States Medicare population. Ann Surg Oncol 20(1):102–110PubMedCentralCrossRefPubMed
9.
go back to reference Han D, Hogeveen S, Sweet Goldstein M et al (2012) Is knowledge translation adequate? A quality assurance study of staging investigations in early stage breast cancer patients. Breast Cancer Res Treat 132(1):1–7CrossRefPubMed Han D, Hogeveen S, Sweet Goldstein M et al (2012) Is knowledge translation adequate? A quality assurance study of staging investigations in early stage breast cancer patients. Breast Cancer Res Treat 132(1):1–7CrossRefPubMed
10.
go back to reference James JJ, McMahon MA, Tennant SL, Cornford EJ (2012) CT staging for breast cancer patients with poor prognostic tumours. Breast 21(6):735–738CrossRefPubMed James JJ, McMahon MA, Tennant SL, Cornford EJ (2012) CT staging for breast cancer patients with poor prognostic tumours. Breast 21(6):735–738CrossRefPubMed
11.
go back to reference Morris PG, O’Connor M, O’Rafferty C et al (2009) The excessive cost of baseline diagnostic imaging in early breast cancer. Ir Med J 102(5):149–152PubMed Morris PG, O’Connor M, O’Rafferty C et al (2009) The excessive cost of baseline diagnostic imaging in early breast cancer. Ir Med J 102(5):149–152PubMed
12.
go back to reference Yeh KA, Fortunato L, Ridge JA, Hoffman JP, Eisenberg BL, Sigurdson ER (1995) Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money. Ann Surg Oncol 2(4):319–324CrossRefPubMed Yeh KA, Fortunato L, Ridge JA, Hoffman JP, Eisenberg BL, Sigurdson ER (1995) Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money. Ann Surg Oncol 2(4):319–324CrossRefPubMed
13.
go back to reference Truong MT, Ko JP, Rossi SE et al (2014) Update in the evaluation of the solitary pulmonary nodule. Radiographics 34(6):1658–1679CrossRefPubMed Truong MT, Ko JP, Rossi SE et al (2014) Update in the evaluation of the solitary pulmonary nodule. Radiographics 34(6):1658–1679CrossRefPubMed
14.
go back to reference MacMahon H, Austin JH, Gamsu G et al (2005) Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: a Statement from the Fleischner Society. Radiology 237(2):395–400CrossRefPubMed MacMahon H, Austin JH, Gamsu G et al (2005) Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: a Statement from the Fleischner Society. Radiology 237(2):395–400CrossRefPubMed
15.
go back to reference Lee B, Lim A, Lalvani A et al (2008) The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. Ann Oncol 19(12):2001–2006PubMedCentralCrossRefPubMed Lee B, Lim A, Lalvani A et al (2008) The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer. Ann Oncol 19(12):2001–2006PubMedCentralCrossRefPubMed
16.
go back to reference Hahn EE, Tang T, Lee JS et al (2015) Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a choosing wisely recommendation. J Oncol Pract. 11(3):e320–e328CrossRefPubMed Hahn EE, Tang T, Lee JS et al (2015) Use of imaging for staging of early-stage breast cancer in two integrated health care systems: adherence with a choosing wisely recommendation. J Oncol Pract. 11(3):e320–e328CrossRefPubMed
17.
go back to reference Ramsey SD, Henry NL, Gralow JR et al (2015) Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol 33(2):149–155PubMedCentralCrossRefPubMed Ramsey SD, Henry NL, Gralow JR et al (2015) Tumor marker usage and medical care costs among older early-stage breast cancer survivors. J Clin Oncol 33(2):149–155PubMedCentralCrossRefPubMed
18.
go back to reference Brennan ME, Houssami N (2012) Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast 21(2):112–123CrossRefPubMed Brennan ME, Houssami N (2012) Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast 21(2):112–123CrossRefPubMed
19.
go back to reference Brennan M, Houssami N (2012) Newly diagnosed early breast cancer—an update on pre-operative assessment and staging. Aust Fam Physician 41(11):871–874PubMed Brennan M, Houssami N (2012) Newly diagnosed early breast cancer—an update on pre-operative assessment and staging. Aust Fam Physician 41(11):871–874PubMed
20.
go back to reference Daglar G, Yuksek YN, Gozalan U, Tutuncu T, Kama NA (2010) The significance of pulmonary nodule in breast cancer patients. Bratisl Lek Listy 111(5):280–283PubMed Daglar G, Yuksek YN, Gozalan U, Tutuncu T, Kama NA (2010) The significance of pulmonary nodule in breast cancer patients. Bratisl Lek Listy 111(5):280–283PubMed
21.
go back to reference Khatcheressian JL, Wolff AC, Smith TJ et al (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091–5097CrossRefPubMed Khatcheressian JL, Wolff AC, Smith TJ et al (2006) American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol 24(31):5091–5097CrossRefPubMed
22.
go back to reference Al-Mutairi A, Meyer AN, Chang P, Singh H (2015) Lack of timely follow-up of abnormal imaging results and radiologists’ recommendations. J Am College Radiol 12(4):385–389CrossRef Al-Mutairi A, Meyer AN, Chang P, Singh H (2015) Lack of timely follow-up of abnormal imaging results and radiologists’ recommendations. J Am College Radiol 12(4):385–389CrossRef
23.
go back to reference Blagev DP, Lloyd JF, Conner K et al (2014) Follow-up of incidental pulmonary nodules and the radiology report. J Am College Radiol 11(4):378–383CrossRef Blagev DP, Lloyd JF, Conner K et al (2014) Follow-up of incidental pulmonary nodules and the radiology report. J Am College Radiol 11(4):378–383CrossRef
24.
go back to reference Dutta S, Long WJ, Brown DF, Reisner AT (2013) Automated detection using natural language processing of radiologists recommendations for additional imaging of incidental findings. Ann Emerg Med 62(2):162–169CrossRefPubMed Dutta S, Long WJ, Brown DF, Reisner AT (2013) Automated detection using natural language processing of radiologists recommendations for additional imaging of incidental findings. Ann Emerg Med 62(2):162–169CrossRefPubMed
Metadata
Title
Incidental radiologic findings at breast cancer diagnosis and likelihood of disease recurrence
Authors
Joel M. Brothers
Kelley M. Kidwell
Richard K. J. Brown
N. Lynn Henry
Publication date
01-01-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3687-1

Other articles of this Issue 2/2016

Breast Cancer Research and Treatment 2/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine